Quadramet(samarium sm 153 lexidronam pentasodium)
Quadramet (samarium sm 153 lexidronam pentasodium) is a small molecule pharmaceutical. Samarium sm 153 lexidronam pentasodium was first approved as Quadramet on 1997-03-28. It has been approved in Europe to treat acer and pain.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Samarium sm-153 lexidronam pentasodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QUADRAMET | Lantheus Medical Imaging | N-020570 DISCN | 1997-03-28 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | 1 | 3 | 5 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | — | — | 1 | 1 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 1 | — | 1 | ||
| Familial primary pulmonary hypertension | D065627 | I27.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | 3 | 4 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiation exposure | D000069079 | — | — | — | — | 2 | 2 | ||
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | 1 | ||
| Esophageal neoplasms | D004938 | C15 | — | — | — | — | 1 | 1 | |
| Lung neoplasms | D008175 | C34.90 | — | — | — | — | 1 | 1 | |
| Myocardial reperfusion | D015425 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SAMARIUM SM 153 LEXIDRONAM PENTASODIUM |
| INN | — |
| Description | Samarium (153Sm) lexidronam (chemical name Samarium-153-ethylene diamine tetramethylene phosphonate, abbreviated Samarium-153 EDTMP, trade name Quadramet) is a chelated complex of a radioisotope of the element samarium with EDTMP. It is used to treat pain when cancer has spread to the bone.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=P([O-])([O-])CN(CCN(CP(=O)([O-])[O-])CP(=O)([O-])[O-])CP(=O)([O-])[O-].[153Sm+3].[Na+].[Na+].[Na+].[Na+].[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 160369-78-8 |
| RxCUI | 317675 |
| ChEMBL ID | CHEMBL2096660 |
| ChEBI ID | — |
| PubChem CID | 9810246 |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 126 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
94 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more